Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
2 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Kyverna Therapeutics, Inc.’s names, not what it holds today.
Patents granted
2
2 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and none in 2023
Applications published
14
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Kyverna Therapeutics, Inc. its own name
named as the applicant on its applications, in US
10 publishedKyverna Therapeutics, Inc. its own name
US, as the owner printed on each patent
4 published
Newest grantseach row opens the USPTO’s own copy
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jan 30, 2025 | 2025/0032614 | METHODS FOR TREATING STIFF PERSON SYNDROME AND MYASTHENIA GRAVIS USING ANTI-CD19 CAR-T CELL THERAPEUTICS | Pharmaceuticals | Kyverna Therapeutics, Inc. |
| Dec 26, 2024 | 2024/0424100 | METHODS OF TREATING LUPUS NEPHRITIS USING ANTI-CD19 CAR-T CELL THERAPIES | Medical technology | Kyverna Therapeutics, Inc. |
| Aug 8, 2024 | 2024/0261405 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE | Biotechnology | Kyverna Therapeutics, Inc. |
| May 16, 2024 | 2024/0158459 | METHODS FOR INCREASING T-CELL FUNCTION | Biotechnology | Kyverna Therapeutics, Inc. |
| Dec 14, 2023 | 2023/0399375 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE | Medical technology | Kyverna Therapeutics, Inc. |
| Oct 19, 2023 | 2023/0330141 | METHODS OF PRODUCING T REGULATORY CELLS, METHODS OF TRANSDUCING T CELLS, AND USES OF THE SAME | Biotechnology | Kyverna Therapeutics, Inc. |
| Jul 6, 2023 | 2023/0210900 | METHODS FOR TREATING AUTOIMMUNE DISEASES | Pharmaceuticals | Kyverna Therapeutics, Inc. |
| Jun 8, 2023 | 2023/0174615 | METHODS FOR INCREASING T-CELL FUNCTION | Biotechnology | Kyverna Therapeutics, Inc. · patent 11,879,003 granted from it |
| Apr 6, 2023 | 2023/0104151 | A METHOD FOR TREATING DISEASE USING FOXP3+CD4+ T CELLS | Biotechnology | Kyverna Therapeutics, Inc. |
| Feb 23, 2023 | 2023/0056336 | METHODS AND COMPOSITIONS FOR TREATING DISEASE USING TARGETED FOXP3+CD4+ T CELLS AND CELLULAR SUICIDE AGENTS | Biotechnology | Kyverna Therapeutics, Inc. |
What it applied for, 2024 to 2025: Biotechnology 2 · Medical technology 1 · Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.